Candidiasis Pipeline Therapeutics Development Review H2 2015

Press Release   •   Dec 01, 2015 08:43 EST

This report provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on H2, 2015 Pipeline Review of “Candidiasis” addition with 43 market data tables and 15 figures, spread across 140 pages is .

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by publisher's team. Drug profiles/records featured in the report undergoes periodic updating following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Companies Discussed/Mentioned in this Research:

Aureogen Biosciences, Inc., Bakker Medical Srl, Biomar Microbial Technologies, Cellceutix Corporation, Cidara Therapeutics, Inc., Daewoong Pharmaceutical Co., Ltd., Eisai Co. Ltd., General Biologicals Corporation, GlaxoSmithKline Plc, Grupo Ferrer Internacional S.A., Hsiri Therapeutics LLC, iCo Therapeutics Inc., Nanomerics Ltd, Novabiotics Limited, NovaDigm Therapeutics, Inc., Onxeo SA, Panacela Labs, Inc., Scynexis, Inc., Sealife PHARMA GMBH, Sequella Inc., Viamet Pharmaceuticals, Inc. and Wellstat Vaccines LLC

Drugs Profile Discussed in this Research:

AC-17, amphotericin b, amphotericin B, arasertaconazole, AUGC-10, AUGC-15, candida vaccine, candida vaccine, candidiasis oligosaccharide vaccine, CD-101, CTIX-1502, DWP-06081, E-1210, E-1211, Forazoline A, KSL-W, MH-010, miconazole, Monoclonal Antibodies to Target Fba for Candidiasis, mutanobactins, Myc-102, NDV-3, NDV-3A, NP-339, obliquumol, PAC-113, pegylated amphotericin B, PMX-1408, PMX-1570, PMX-1576, PMX-1591, PMX-1625, PMX-519, PMX-70004, Prof-002, Recombinant Peptides for Oropharyngeal Candidiasis, SCY-078, SLP-0901, SLP-0904, Small Molecule for Candidiasis, Small Molecule for Fungal Infections, Small Molecule for Systemic Candidiasis, Small Molecules for Aspergillosis and Candidiasis, Small Molecules for Candidiasis, Small Molecules for Fungal Infections, SQ-109, VT-1161 and XELRYX-3

Inquire before buying for this report . (This is a premium report price at US$2000 for a single user PDF license)


  • The report provides a snapshot of the global therapeutic landscape of Candidiasis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Candidiasis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Candidiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Candidiasis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Candidiasis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore More Research Report on Infectious Diseases Therapeutics Market. is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries